D.C. Denies Prostate Cancer Vaccine, Provenge: Dendreon (WA) Not FDA To Blame

Many in the prostate cancer community are still outraged over the FDA’s decision to deny approval for the immunotherapy drug Provenge. Some have even gone as far as to make threats against Howard I. Scher of Memorial Sloan-Kettering Cancer Center (NY) and Maha Hussain of University of Michigan, two physicians who influenced this decision.

However, Dr. Charles “Snuffy” Myers, leading PC oncologist and VA prostate cancer survivor, remains staunch in his objections to the trials Dendreon presented to the FDA despite the benefits the drug might bring to his patients and himself. Myers has written extensively on this subject in his Prostate Forum newsletters 10 #01 and 10 #02, available at http://www.prostateforum.com.

“Dendreon made major and obvious mistakes in developing Provenge. The FDA is not some sort of bad guy — at least in this case and yet Dendreon’s stock continues to rise,” Myers’ says. “The primary end point of a clinical trial seeking FDA approval should be either survival or improved quality of life, but Dendreon still chose to muddy the waters by changing endpoints midway through the clinical trial, forcing the FDA’s hand with their poor design.”

“This is actually the second time that we’ve had a useful drug fail in development. The other was Atrasentan (a.k.a. Xinlay),” Myers adds. “Again, it failed not because of the FDA but because of drug company incompetence. While the FDA is far from perfect, people need to understand who to blame in this case.”

“I can understand the anger,” Myers says, “but is it really unreasonable to ask for proof that a drug is safe and either improves survival or quality of life? I think that Provenge is an active agent with a definite, but limited, benefit, so I feel a personal loss now that it is not going to be available. But killing the messenger doesn’t change the message; it just obscures the real problem — and solving problems is what modern medicine should really be about.”

Leave a Reply